Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone loss

被引：1

作者：

Hahn, Bevra H. ^{[1
]}

Hahn, Theodore J.

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA

[2] W Los Angeles Vet Adm Hlth Care Ctr, Los Angeles, CA USA

来源：

NATURE CLINICAL PRACTICE RHEUMATOLOGY | 2007年 / 3卷 / 01期

关键词：

alendronate; alfacalcidol; glucocorticoids; osteoporosis; prevention;

D O I：

10.1038/ncprheum0370

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10 / 11

页数：2

共 4 条

[1] ALTERED MINERAL METABOLISM IN GLUCOCORTICOID-INDUCED OSTEOPENIA - EFFECT OF 25-HYDROXYVITAMIN-D ADMINISTRATION [J].

HAHN, TJ ;

HALSTEAD, LR ;

TEITELBAUM, SL ;

HAHN, BH .

JOURNAL OF CLINICAL INVESTIGATION, 1979, 64 (02) :655-665

[2]

Holick Michael F, 2006, Curr Osteoporos Rep, V4, P96, DOI 10.1007/BF02686953

[3] Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis [J].

Luckey, MM ;

Gilchrist, N ;

Bone, HG ;

Davie, MW ;

de Villiers, TJ ;

Wu, M ;

Daifotis, AG ;

Santora, AC ;

Orloff, A .

OBSTETRICS AND GYNECOLOGY, 2003, 101 (04) :711-721

[4] Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis [J].

Richy, F ;

Schacht, E ;

Bruyere, O ;

Ethgen, O ;

Gourlay, M ;

Reginster, JY .

CALCIFIED TISSUE INTERNATIONAL, 2005, 76 (03) :176-186

← 1 →